Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Policy Director Elizabeth Cobbs On Strategic Focus And Pipeline Of Banyu, And On Parent Merck, in Japan: An Interview with PharmAsia News, Part 1

This article was originally published in PharmAsia News

Executive Summary

Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharmaceutical concern, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.
Advertisement

Related Content

Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Advertisement
UsernamePublicRestriction

Register

SC071320

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel